Ipilimumab for Patients with Relapse after Allogeneic Transplantation

BACKGROUND: Loss of donor-mediated immune antitumor activity after allogeneic hematopoietic stem-cell transplantation (HSCT) permits relapse of hematologic cancers. We hypothesized that immune checkpoint blockade established by targeting cytotoxic T-lymphocyte–associated protein 4 with ipilimumab co...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:N Engl J Med
Autori principali: Davids, Matthew S., Kim, Haesook T., Bachireddy, Pavan, Costello, Caitlin, Liguori, Rebecca, Savell, Alexandra, Lukez, Alexander P., Avigan, David, Chen, Yi-Bin, McSweeney, Peter, LeBoeuf, Nicole R., Rooney, Michael S., Bowden, Michaela, Zhou, Chensheng W., Granter, Scott R., Hornick, Jason L., Rodig, Scott J., Hirakawa, Masahiro, Severgnini, Mariano, Hodi, F. Stephen, Wu, Catherine J., Ho, Vincent T., Cutler, Corey, Koreth, John, Alyea, Edwin P., Antin, Joseph H., Armand, Philippe, Streicher, Howard, Ball, Edward D., Ritz, Jerome, Bashey, Asad, Soiffer, Robert J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5149459/
https://ncbi.nlm.nih.gov/pubmed/27410923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1601202
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi